Endocrine Abstracts (2009) 20 P359

Saxagliptin either as add-on therapy to metformin or as initial combination therapy with metformin improves glycaemic control in patients with type 2 diabetes

Andreas Pfützner1, Irina Gurieva2, Mikhail Antsiferov3, Elsie Allen4, Shoba Ravichandran4 & Roland Chen4


1Institute for Clinical Research and Development, Mainz, Germany; 2Federal Bureau of Medicine and Social Expertise, Moscow, Russian Federation; 3Endocrinology Dispensary, Moscow, Russian Federation; 4Global Clinical Research, Bristol-Myers Squibb, Princeton, New Jersey, USA.


The efficacy and safety of saxagliptin – a potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor, specifically designed for extended inhibition of the DPP-4 enzyme – was investigated in two double-blind, randomised trials (CV181-014/Study 1 and CV181-039/Study 2), either as add-on therapy in patients with type 2 diabetes mellitus (T2DM) inadequately controlled by metformin alone (HbA1c 7.0–10.0%) or as initial combination therapy with metformin in drug-naïve T2DM patients (HbA1c 8.0–12.0%), respectively.

Following a placebo run-in, patients with inadequately controlled T2DM (n=743) on metformin, in Study 1, were randomised to receive once-daily saxagliptin 2.5, 5.0 or 10.0 mg, or placebo, plus their stable metformin dose, and drug-naïve patients (n=1306), in Study 2, were randomised to receive saxagliptin/metformin 5/500 mg (S5/MET), 10/500 mg (S10/MET), saxagliptin 10 mg or metformin 500 mg once-daily. In the S5/MET, S10/MET and metformin alone treatment groups of Study 2, metformin was up-titrated incrementally (Weeks 1–5) to a maximum of 2000 mg/day. Both studies’ primary endpoint was HbA1c change from baseline. Treatment groups were well balanced for baseline characteristics within each study.

At week 24, significant (P<0.0001) reductions in adjusted-mean HbA1c change from baseline were observed in Study 1 for saxagliptin 2.5, 5.0 and 10.0 mg (−0.59, −0.69 and −0.58%, respectively), compared with placebo (0.13%), and in Study 2 for S5/MET (−2.53%) and S10/MET (−2.49%), compared with saxagliptin (−1.69%) or metformin (−1.99%) alone. In each study, saxagliptin plus metformin provided significant (P<0.001) reductions in fasting plasma glucose and postprandial glucose, increased proportions of patients with therapeutic glycaemic response (HbA1c<7%), and was well tolerated with no increased incidence of hypoglycaemia compared with matched controls. Saxagliptin add-on or initial combination therapy with metformin provides significant and clinically meaningful reductions in key parameters of glycaemic control and is well tolerated in patients with inadequately controlled T2DM.

Article tools

My recent searches

No recent searches.